← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Albiglutide

FDA approved · Rx

GLP-1 receptor agonist

Also known as: Tanzeum, albiglutidum, Albiglutida, Albiglutide (genetical recombination), Eperzan, GSK-716155, AC-38400

Evidence score
88/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 39 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Albiglutide, sold as Tanzeum, is a GLP-1 receptor agonist made by fusing two copies of a modified GLP-1 peptide to human albumin, which extends how long it stays in the body. It acts like the natural hormone GLP-1, increasing glucose-dependent insulin release, reducing glucagon, and slowing stomach emptying.

What the evidence shows

Automatic summaryHuman trials

Albiglutide was approved by the FDA in 2014 for improving blood sugar control in adults with type 2 diabetes, supported by a large phase 3 program and later outcome trials. It was discontinued by its maker in 2018 for commercial reasons, which likely explains why it does not appear in current FDA brand listings.

Key facts

Molecular formula
C148H223N39O46
Molecular weight
3284.6 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

39registered studies
Phase 4most advanced phase
31completed (sample)
0recruiting (sample)

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Phase 3CompletedNCT02787551

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Phase 3CompletedNCT00838916

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Phase 3CompletedNCT00976391

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

Phase 3CompletedNCT00839527

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

282papers referencing Albiglutide

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Lancet2018

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Lancet Diabetes Endocrinol2019

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Mol Metab2021

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Nat Rev Endocrinol2012

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.